APO Research
Talk to an analyst

APO RESEARCH · REPORT

Antisense and RNAi Therapeutics Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Antisense and RNAi Therapeutics Drug Market Outlook and Growth Opportunities 2026

21 December 2025192 pages

Choose your research edition.

Industry ResearchAntisense and RNAi Therapeutics Drug Industry Research Report 2026112 pages · $2,950 USDIndustry Growth & TrendsGlobal Antisense and RNAi Therapeutics Drug Industry Growth and Trends Forecast to 203289 pages · $3,450 USDMarket StructureGlobal Antisense and RNAi Therapeutics Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032188 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Antisense and RNAi Therapeutics Drug Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Antisense and RNAi Therapeutics Drug Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Antisense and RNAi Therapeutics Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Antisense and RNAi Therapeutics Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Antisense and RNAi Therapeutics Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Antisense and RNAi Therapeutics Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Antisense and RNAi Therapeutics Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Antisense and RNAi Therapeutics Drug market include Biogen, Sarepta Therapeutics, Kastle therapeutics, Jazz Pharmaceuticals, Dynavax Technologies, Bausch & Lomb, Alnylam Pharmaceuticals and Akcea Therapeutics, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Antisense and RNAi Therapeutics Drug market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Antisense and RNAi Therapeutics Drug and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Antisense and RNAi Therapeutics Drug revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Antisense and RNAi Therapeutics Drug market.

Antisense and RNAi Therapeutics Drug Segment by Company

Biogen

Sarepta Therapeutics

Kastle therapeutics

Jazz Pharmaceuticals

Dynavax Technologies

Bausch & Lomb

Alnylam Pharmaceuticals

Akcea Therapeutics

Antisense and RNAi Therapeutics Drug Segment by Type

Antisense Oligonucleotide

Aptamer

Other

Antisense and RNAi Therapeutics Drug Segment by Application

ATTR

Hepatic VOD

Neuromuscular Diseases

Other

Antisense and RNAi Therapeutics Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Antisense and RNAi Therapeutics Drug status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Antisense and RNAi Therapeutics Drug key companies, revenue, market share, and recent developments.

3. To split the Antisense and RNAi Therapeutics Drug breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Antisense and RNAi Therapeutics Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Antisense and RNAi Therapeutics Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Antisense and RNAi Therapeutics Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antisense and RNAi Therapeutics Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Antisense and RNAi Therapeutics Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antisense and RNAi Therapeutics Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Antisense and RNAi Therapeutics Drug industry.

Chapter 3: Detailed analysis of Antisense and RNAi Therapeutics Drug company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Antisense and RNAi Therapeutics Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Antisense and RNAi Therapeutics Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Antisense and RNAi Therapeutics Drug Industry Trends Table 2. Antisense and RNAi Therapeutics Drug Industry Drivers Table 3. Antisense and RNAi Therapeutics Drug Industry Opportunities and Challenges Table 4. Antisense and RNAi Therapeutics Drug Industry Restraints Table 5. Global Antisense and RNAi Therapeutics Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Antisense and RNAi Therapeutics Drug Revenue Share by Company (2021-2026) Table 7. Global Antisense and RNAi Therapeutics Drug Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Antisense and RNAi Therapeutics Drug Key Company Manufacturing Base & Headquarters Table 9. Global Antisense and RNAi Therapeutics Drug Company, Product Type & Application Table 10. Global Antisense and RNAi Therapeutics Drug Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Antisense and RNAi Therapeutics Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Antisense Oligonucleotide Table 15. Significant Companies of Aptamer Table 16. Significant Companies of Other Table 17. Global Antisense and RNAi Therapeutics Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Antisense and RNAi Therapeutics Drug Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Antisense and RNAi Therapeutics Drug Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Antisense and RNAi Therapeutics Drug Sales Value Share by Type (2021-2026) Table 21. Global Antisense and RNAi Therapeutics Drug Sales Value Share by Type (2027-2032) Table 22. Significant Companies of ATTR Table 23. Significant Companies of Hepatic VOD Table 24. Significant Companies of Neuromuscular Diseases Table 25. Significant Companies of Other Table 26. Global Antisense and RNAi Therapeutics Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Antisense and RNAi Therapeutics Drug Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Antisense and RNAi Therapeutics Drug Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Antisense and RNAi Therapeutics Drug Sales Value Share by Application (2021-2026) Table 30. Global Antisense and RNAi Therapeutics Drug Sales Value Share by Application (2027-2032) Table 31. Global Antisense and RNAi Therapeutics Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Antisense and RNAi Therapeutics Drug Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Antisense and RNAi Therapeutics Drug Sales Value Share by Region (2021-2026) Table 34. Global Antisense and RNAi Therapeutics Drug Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Antisense and RNAi Therapeutics Drug Sales Value Share by Region (2027-2032) Table 36. Global Antisense and RNAi Therapeutics Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Antisense and RNAi Therapeutics Drug Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Antisense and RNAi Therapeutics Drug Sales Value Market Share by Country (2021-2026) Table 39. Global Antisense and RNAi Therapeutics Drug Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Antisense and RNAi Therapeutics Drug Sales Value Market Share by Country (2027-2032) Table 41. Biogen Company Information Table 42. Biogen Business Overview Table 43. Biogen Antisense and RNAi Therapeutics Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Biogen Antisense and RNAi Therapeutics Drug Product Portfolio Table 45. Biogen Recent Development Table 46. Sarepta Therapeutics Company Information Table 47. Sarepta Therapeutics Business Overview Table 48. Sarepta Therapeutics Antisense and RNAi Therapeutics Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Sarepta Therapeutics Antisense and RNAi Therapeutics Drug Product Portfolio Table 50. Sarepta Therapeutics Recent Development Table 51. Kastle therapeutics Company Information Table 52. Kastle therapeutics Business Overview Table 53. Kastle therapeutics Antisense and RNAi Therapeutics Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Kastle therapeutics Antisense and RNAi Therapeutics Drug Product Portfolio Table 55. Kastle therapeutics Recent Development Table 56. Jazz Pharmaceuticals Company Information Table 57. Jazz Pharmaceuticals Business Overview Table 58. Jazz Pharmaceuticals Antisense and RNAi Therapeutics Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Jazz Pharmaceuticals Antisense and RNAi Therapeutics Drug Product Portfolio Table 60. Jazz Pharmaceuticals Recent Development Table 61. Dynavax Technologies Company Information Table 62. Dynavax Technologies Business Overview Table 63. Dynavax Technologies Antisense and RNAi Therapeutics Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Dynavax Technologies Antisense and RNAi Therapeutics Drug Product Portfolio Table 65. Dynavax Technologies Recent Development Table 66. Bausch & Lomb Company Information Table 67. Bausch & Lomb Business Overview Table 68. Bausch & Lomb Antisense and RNAi Therapeutics Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Bausch & Lomb Antisense and RNAi Therapeutics Drug Product Portfolio Table 70. Bausch & Lomb Recent Development Table 71. Alnylam Pharmaceuticals Company Information Table 72. Alnylam Pharmaceuticals Business Overview Table 73. Alnylam Pharmaceuticals Antisense and RNAi Therapeutics Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Alnylam Pharmaceuticals Antisense and RNAi Therapeutics Drug Product Portfolio Table 75. Alnylam Pharmaceuticals Recent Development Table 76. Akcea Therapeutics Company Information Table 77. Akcea Therapeutics Business Overview Table 78. Akcea Therapeutics Antisense and RNAi Therapeutics Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Akcea Therapeutics Antisense and RNAi Therapeutics Drug Product Portfolio Table 80. Akcea Therapeutics Recent Development Table 81. Research Programs/Design for This Report Table 82. Authors List of This Report Table 83. Secondary Sources Table 84. Primary Sources List of Figures Figure 1. Antisense and RNAi Therapeutics Drug Product Image Figure 2. Global Antisense and RNAi Therapeutics Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Antisense and RNAi Therapeutics Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Antisense and RNAi Therapeutics Drug Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Antisense Oligonucleotide Image Figure 8. Aptamer Image Figure 9. Other Image Figure 10. Global Antisense and RNAi Therapeutics Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Antisense and RNAi Therapeutics Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Antisense and RNAi Therapeutics Drug Sales Value Share by Type (2021-2032) Figure 13. ATTR Image Figure 14. Hepatic VOD Image Figure 15. Neuromuscular Diseases Image Figure 16. Other Image Figure 17. Global Antisense and RNAi Therapeutics Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Antisense and RNAi Therapeutics Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Antisense and RNAi Therapeutics Drug Sales Value Share by Application (2021-2032) Figure 20. Global Antisense and RNAi Therapeutics Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Antisense and RNAi Therapeutics Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Antisense and RNAi Therapeutics Drug Sales Value (2021-2032) & (US$ Million) Figure 23. North America Antisense and RNAi Therapeutics Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Antisense and RNAi Therapeutics Drug Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Antisense and RNAi Therapeutics Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Antisense and RNAi Therapeutics Drug Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Antisense and RNAi Therapeutics Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Antisense and RNAi Therapeutics Drug Sales Value (2021-2032) & (US$ Million) Figure 29. South America Antisense and RNAi Therapeutics Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Antisense and RNAi Therapeutics Drug Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Antisense and RNAi Therapeutics Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Antisense and RNAi Therapeutics Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Antisense and RNAi Therapeutics Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Antisense and RNAi Therapeutics Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Antisense and RNAi Therapeutics Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Antisense and RNAi Therapeutics Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Antisense and RNAi Therapeutics Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Antisense and RNAi Therapeutics Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Antisense and RNAi Therapeutics Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Antisense and RNAi Therapeutics Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Antisense and RNAi Therapeutics Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Antisense and RNAi Therapeutics Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Antisense and RNAi Therapeutics Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Antisense and RNAi Therapeutics Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Antisense and RNAi Therapeutics Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Antisense and RNAi Therapeutics Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Antisense and RNAi Therapeutics Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Antisense and RNAi Therapeutics Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Antisense and RNAi Therapeutics Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Antisense and RNAi Therapeutics Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Antisense and RNAi Therapeutics Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Antisense and RNAi Therapeutics Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Antisense and RNAi Therapeutics Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Antisense and RNAi Therapeutics Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Antisense and RNAi Therapeutics Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Antisense and RNAi Therapeutics Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Antisense and RNAi Therapeutics Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Antisense and RNAi Therapeutics Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Antisense and RNAi Therapeutics Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Antisense and RNAi Therapeutics Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Antisense and RNAi Therapeutics Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Antisense and RNAi Therapeutics Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Antisense and RNAi Therapeutics Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Antisense and RNAi Therapeutics Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Antisense and RNAi Therapeutics Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Antisense and RNAi Therapeutics Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Antisense and RNAi Therapeutics Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Antisense and RNAi Therapeutics Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Antisense and RNAi Therapeutics Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Antisense and RNAi Therapeutics Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Antisense and RNAi Therapeutics Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Antisense and RNAi Therapeutics Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Antisense and RNAi Therapeutics Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Antisense and RNAi Therapeutics Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Antisense and RNAi Therapeutics Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Antisense and RNAi Therapeutics Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Antisense and RNAi Therapeutics Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Antisense and RNAi Therapeutics Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Antisense and RNAi Therapeutics Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Antisense and RNAi Therapeutics Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Antisense and RNAi Therapeutics Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Antisense and RNAi Therapeutics Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Antisense and RNAi Therapeutics Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Antisense and RNAi Therapeutics Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Antisense and RNAi Therapeutics Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Antisense and RNAi Therapeutics Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Antisense and RNAi Therapeutics Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Antisense and RNAi Therapeutics Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Antisense and RNAi Therapeutics Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Antisense and RNAi Therapeutics Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Antisense and RNAi Therapeutics Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Antisense and RNAi Therapeutics Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Antisense and RNAi Therapeutics Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Antisense and RNAi Therapeutics Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Antisense and RNAi Therapeutics Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Antisense and RNAi Therapeutics Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Antisense and RNAi Therapeutics Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Antisense and RNAi Therapeutics Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Antisense and RNAi Therapeutics Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Antisense and RNAi Therapeutics Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Antisense and RNAi Therapeutics Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Antisense and RNAi Therapeutics Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Antisense and RNAi Therapeutics Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Antisense and RNAi Therapeutics Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Antisense and RNAi Therapeutics Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Antisense and RNAi Therapeutics Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Antisense and RNAi Therapeutics Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Antisense and RNAi Therapeutics Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Antisense and RNAi Therapeutics Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Antisense and RNAi Therapeutics Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Antisense and RNAi Therapeutics Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Antisense and RNAi Therapeutics Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Antisense and RNAi Therapeutics Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Antisense and RNAi Therapeutics Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Antisense and RNAi Therapeutics Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Antisense Oligonucleotide
  • Aptamer
  • Other
Applications
  • ATTR
  • Hepatic VOD
  • Neuromuscular Diseases
  • Other
Companies covered
  • Biogen
  • Sarepta Therapeutics
  • Kastle therapeutics
  • Jazz Pharmaceuticals
  • Dynavax Technologies
  • Bausch & Lomb
  • Alnylam Pharmaceuticals
  • Akcea Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Antisense and RNAi Therapeutics Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Antisense and RNAi Therapeutics Drug Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Antisense and RNAi Therapeutics Drug Market Dynamics
  1. 2.1 Antisense and RNAi Therapeutics Drug Industry Trends
  2. 2.2 Antisense and RNAi Therapeutics Drug Industry Drivers
  3. 2.3 Antisense and RNAi Therapeutics Drug Industry Opportunities and Challenges
  4. 2.4 Antisense and RNAi Therapeutics Drug Industry Restraints
3 Antisense and RNAi Therapeutics Drug Market by Company
  1. 3.1 Global Antisense and RNAi Therapeutics Drug Company Revenue Ranking in 2025
  2. 3.2 Global Antisense and RNAi Therapeutics Drug Revenue by Company (2021-2026)
  3. 3.3 Global Antisense and RNAi Therapeutics Drug Company Ranking (2024-2026)
  4. 3.4 Global Antisense and RNAi Therapeutics Drug Company Manufacturing Base and Headquarters
  5. 3.5 Global Antisense and RNAi Therapeutics Drug Company Product Type and Application
  6. 3.6 Global Antisense and RNAi Therapeutics Drug Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Antisense and RNAi Therapeutics Drug Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Antisense and RNAi Therapeutics Drug Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Antisense and RNAi Therapeutics Drug Market by Type
  1. 4.1 Antisense and RNAi Therapeutics Drug Type Introduction
  2. 4.1.1 Antisense Oligonucleotide
  3. 4.1.2 Aptamer
  4. 4.1.3 Other
  5. 4.2 Global Antisense and RNAi Therapeutics Drug Sales Value by Type
  6. 4.2.1 Global Antisense and RNAi Therapeutics Drug Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Antisense and RNAi Therapeutics Drug Sales Value by Type (2021-2032)
  8. 4.2.3 Global Antisense and RNAi Therapeutics Drug Sales Value Share by Type (2021-2032)
5 Antisense and RNAi Therapeutics Drug Market by Application
  1. 5.1 Antisense and RNAi Therapeutics Drug Application Introduction
  2. 5.1.1 ATTR
  3. 5.1.2 Hepatic VOD
  4. 5.1.3 Neuromuscular Diseases
  5. 5.1.4 Other
  6. 5.2 Global Antisense and RNAi Therapeutics Drug Sales Value by Application
  7. 5.2.1 Global Antisense and RNAi Therapeutics Drug Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Antisense and RNAi Therapeutics Drug Sales Value by Application (2021-2032)
  9. 5.2.3 Global Antisense and RNAi Therapeutics Drug Sales Value Share by Application (2021-2032)
6 Antisense and RNAi Therapeutics Drug Regional Value Analysis
  1. 6.1 Global Antisense and RNAi Therapeutics Drug Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Antisense and RNAi Therapeutics Drug Sales Value by Region (2021-2032)
  3. 6.2.1 Global Antisense and RNAi Therapeutics Drug Sales Value by Region: 2021-2026
  4. 6.2.2 Global Antisense and RNAi Therapeutics Drug Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Antisense and RNAi Therapeutics Drug Sales Value (2021-2032)
  7. 6.3.2 North America Antisense and RNAi Therapeutics Drug Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Antisense and RNAi Therapeutics Drug Sales Value (2021-2032)
  10. 6.4.2 Europe Antisense and RNAi Therapeutics Drug Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Antisense and RNAi Therapeutics Drug Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Antisense and RNAi Therapeutics Drug Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Antisense and RNAi Therapeutics Drug Sales Value (2021-2032)
  16. 6.6.2 South America Antisense and RNAi Therapeutics Drug Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Antisense and RNAi Therapeutics Drug Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Antisense and RNAi Therapeutics Drug Sales Value Share by Country, 2025 VS 2032
7 Antisense and RNAi Therapeutics Drug Country-level Value Analysis
  1. 7.1 Global Antisense and RNAi Therapeutics Drug Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Antisense and RNAi Therapeutics Drug Sales Value by Country (2021-2032)
  3. 7.2.1 Global Antisense and RNAi Therapeutics Drug Sales Value by Country (2021-2026)
  4. 7.2.2 Global Antisense and RNAi Therapeutics Drug Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Antisense and RNAi Therapeutics Drug Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Antisense and RNAi Therapeutics Drug Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Antisense and RNAi Therapeutics Drug Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Antisense and RNAi Therapeutics Drug Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Antisense and RNAi Therapeutics Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Antisense and RNAi Therapeutics Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Antisense and RNAi Therapeutics Drug Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Antisense and RNAi Therapeutics Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Antisense and RNAi Therapeutics Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Antisense and RNAi Therapeutics Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Antisense and RNAi Therapeutics Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Antisense and RNAi Therapeutics Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Antisense and RNAi Therapeutics Drug Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Antisense and RNAi Therapeutics Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Antisense and RNAi Therapeutics Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Antisense and RNAi Therapeutics Drug Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Antisense and RNAi Therapeutics Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Antisense and RNAi Therapeutics Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Antisense and RNAi Therapeutics Drug Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Antisense and RNAi Therapeutics Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Antisense and RNAi Therapeutics Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Antisense and RNAi Therapeutics Drug Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Antisense and RNAi Therapeutics Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Antisense and RNAi Therapeutics Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Antisense and RNAi Therapeutics Drug Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Antisense and RNAi Therapeutics Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Antisense and RNAi Therapeutics Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Antisense and RNAi Therapeutics Drug Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Antisense and RNAi Therapeutics Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Antisense and RNAi Therapeutics Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Antisense and RNAi Therapeutics Drug Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Antisense and RNAi Therapeutics Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Antisense and RNAi Therapeutics Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Antisense and RNAi Therapeutics Drug Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Antisense and RNAi Therapeutics Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Antisense and RNAi Therapeutics Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Antisense and RNAi Therapeutics Drug Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Antisense and RNAi Therapeutics Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Antisense and RNAi Therapeutics Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Antisense and RNAi Therapeutics Drug Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Antisense and RNAi Therapeutics Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Antisense and RNAi Therapeutics Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Antisense and RNAi Therapeutics Drug Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Antisense and RNAi Therapeutics Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Antisense and RNAi Therapeutics Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Antisense and RNAi Therapeutics Drug Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Antisense and RNAi Therapeutics Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Antisense and RNAi Therapeutics Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Antisense and RNAi Therapeutics Drug Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Antisense and RNAi Therapeutics Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Antisense and RNAi Therapeutics Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Antisense and RNAi Therapeutics Drug Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Antisense and RNAi Therapeutics Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Antisense and RNAi Therapeutics Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Antisense and RNAi Therapeutics Drug Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Antisense and RNAi Therapeutics Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Antisense and RNAi Therapeutics Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Antisense and RNAi Therapeutics Drug Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Antisense and RNAi Therapeutics Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Antisense and RNAi Therapeutics Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Antisense and RNAi Therapeutics Drug Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Antisense and RNAi Therapeutics Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Antisense and RNAi Therapeutics Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Antisense and RNAi Therapeutics Drug Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Antisense and RNAi Therapeutics Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Antisense and RNAi Therapeutics Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Antisense and RNAi Therapeutics Drug Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Antisense and RNAi Therapeutics Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Antisense and RNAi Therapeutics Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Antisense and RNAi Therapeutics Drug Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Antisense and RNAi Therapeutics Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Antisense and RNAi Therapeutics Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Antisense and RNAi Therapeutics Drug Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Antisense and RNAi Therapeutics Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Antisense and RNAi Therapeutics Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Antisense and RNAi Therapeutics Drug Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Antisense and RNAi Therapeutics Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Antisense and RNAi Therapeutics Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Antisense and RNAi Therapeutics Drug Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Antisense and RNAi Therapeutics Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Antisense and RNAi Therapeutics Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Antisense and RNAi Therapeutics Drug Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Antisense and RNAi Therapeutics Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Antisense and RNAi Therapeutics Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Biogen
  2. 8.1.1 Biogen Company Information
  3. 8.1.2 Biogen Business Overview
  4. 8.1.3 Biogen Antisense and RNAi Therapeutics Drug Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Biogen Antisense and RNAi Therapeutics Drug Product Portfolio
  6. 8.1.5 Biogen Recent Developments
  7. 8.2 Sarepta Therapeutics
  8. 8.2.1 Sarepta Therapeutics Company Information
  9. 8.2.2 Sarepta Therapeutics Business Overview
  10. 8.2.3 Sarepta Therapeutics Antisense and RNAi Therapeutics Drug Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Sarepta Therapeutics Antisense and RNAi Therapeutics Drug Product Portfolio
  12. 8.2.5 Sarepta Therapeutics Recent Developments
  13. 8.3 Kastle therapeutics
  14. 8.3.1 Kastle therapeutics Company Information
  15. 8.3.2 Kastle therapeutics Business Overview
  16. 8.3.3 Kastle therapeutics Antisense and RNAi Therapeutics Drug Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Kastle therapeutics Antisense and RNAi Therapeutics Drug Product Portfolio
  18. 8.3.5 Kastle therapeutics Recent Developments
  19. 8.4 Jazz Pharmaceuticals
  20. 8.4.1 Jazz Pharmaceuticals Company Information
  21. 8.4.2 Jazz Pharmaceuticals Business Overview
  22. 8.4.3 Jazz Pharmaceuticals Antisense and RNAi Therapeutics Drug Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Jazz Pharmaceuticals Antisense and RNAi Therapeutics Drug Product Portfolio
  24. 8.4.5 Jazz Pharmaceuticals Recent Developments
  25. 8.5 Dynavax Technologies
  26. 8.5.1 Dynavax Technologies Company Information
  27. 8.5.2 Dynavax Technologies Business Overview
  28. 8.5.3 Dynavax Technologies Antisense and RNAi Therapeutics Drug Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Dynavax Technologies Antisense and RNAi Therapeutics Drug Product Portfolio
  30. 8.5.5 Dynavax Technologies Recent Developments
  31. 8.6 Bausch & Lomb
  32. 8.6.1 Bausch & Lomb Company Information
  33. 8.6.2 Bausch & Lomb Business Overview
  34. 8.6.3 Bausch & Lomb Antisense and RNAi Therapeutics Drug Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Bausch & Lomb Antisense and RNAi Therapeutics Drug Product Portfolio
  36. 8.6.5 Bausch & Lomb Recent Developments
  37. 8.7 Alnylam Pharmaceuticals
  38. 8.7.1 Alnylam Pharmaceuticals Company Information
  39. 8.7.2 Alnylam Pharmaceuticals Business Overview
  40. 8.7.3 Alnylam Pharmaceuticals Antisense and RNAi Therapeutics Drug Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Alnylam Pharmaceuticals Antisense and RNAi Therapeutics Drug Product Portfolio
  42. 8.7.5 Alnylam Pharmaceuticals Recent Developments
  43. 8.8 Akcea Therapeutics
  44. 8.8.1 Akcea Therapeutics Company Information
  45. 8.8.2 Akcea Therapeutics Business Overview
  46. 8.8.3 Akcea Therapeutics Antisense and RNAi Therapeutics Drug Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Akcea Therapeutics Antisense and RNAi Therapeutics Drug Product Portfolio
  48. 8.8.5 Akcea Therapeutics Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst